Arcadia Biosciences, Inc. RKDA
Oil & Gas Production · IPO 2015 · data as of November 13, 2026
Arcadia Biosciences, Inc. (RKDA) is a energy company listed in the US with a market value of about $1M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$10M, a net margin of -202.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of -51%.
About Arcadia Biosciences
Arcadia Biosciences is listed in the US and classified in oil & gas production, IPO year 2015. Revenue went from $7M in 2014 to $5M in 2025, a decline of about 3.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 128% over three years (dilution for shareholders). It spends 0% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $5M | $5M | $4M | $7M | $7M | $8M | $1M | $1M | $4M | $3M |
| Net income | -$10M | -$2M | -$7M | -$14M | -$15M | -$15M | -$5M | -$29M | -$13M | -$16M | -$20M |
| Free cash flow | — | -$5M | -$10M | -$15M | -$14M | -$27M | -$33M | -$19M | -$14M | -$14M | -$17M |
| EPS (diluted) | $-4.89 | $-1.71 | $-5.17 | $-11.29 | $-25.65 | $-27.56 | $-0.47 | $-4.53 | $-3.58 | $-7.28 | $-8.85 |
| Net margin | -202.1% | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% | -57.9% | -2464.1% | -920.8% | -390.1% | -615.6% |
| ROIC | — | -47.7% | -45.2% | -34.8% | -48.0% | -81.6% | -33.8% | -154.0% | -104.0% | -141.2% | -31.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Arcadia Biosciences pay a dividend?
Not currently.
Is Arcadia Biosciences a good stock to buy?
We do not give buy or sell advice. Arcadia Biosciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.